Drugs / grass pollen allergen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00241410 | Dec 2005 → Jan 2007 | hypersensitivity reaction disease | Allergy Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-16 | Allergy Therapeutics | Regulatory Grassmuno® marketing authorisation in Germany allergytherapeutics.com ↗
Allergy Therapeutics granted marketing authorisation for Grassmuno ® (Grass MATA MPL) by the German regulatory authority, the Paul Ehrlich Institut |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-16 | Allergy Therapeutics | Grassmuno® marketing authorisation in Germany allergytherapeutics.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | grass pollen allergen | “MPL and/or grass pollen allergen” NCT00241410 ↗ |